BioSpace News Archive

Tenaya Therapeutics, Inc. announced today that Faraz Ali, Chief Executive Officer, is scheduled to participate in the Chardan 6th Annual Genetic Medicines Conference and the Alliance for Regenerative Medicine’s Cell and Gene Meeting on the Mesa.

Recludix Pharma announced the appointment of Matthew Caldemeyer as chief business officer.

Ayala Pharmaceuticals, Inc. announced that it will host a key opinion leader webinar on unmet medical needs and evolving treatment landscape of desmoid tumors on Thursday, October 6, 2022, at 8:00 am ET.

aTyr Pharma, Inc., a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, announced that the U.S. Patent and Trademark Office has provided a Notice of Allowance for a patent covering methods for the use of anti-neuropilin-2 antibodies.

Selecta Biosciences, Inc. extends its congratulations to its board of directors member, Timothy Springer, Ph.D., who yesterday won the Albert Lasker Basic Medical Research Award for his seminal discovery of integrin adhesion molecules that regulate trafficking, cell-cell interactions, and effector functions of lymphocytes and other immune cells.

CRISPR Therapeutics, a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, announced that members of its senior management team are scheduled to participate in the BMO Biopharma Spotlight Series: Gene Editing and Therapy on Thursday, October 6, 2022, at 9:00 a.m. ET.

Lisata Therapeutics, Inc. announced that Erkki Ruoslahti, M.D., Ph.D., the scientific founder of the Company’s CendR Platform™ technology and a member of the Company’s board of directors, was a recipient of the 2022 Albert Lasker Basic Medical Research Award, which was awarded on September 28, 2022.

Solid Biosciences Inc., a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy, announced that Ilan Ganot, Co-Founder, President and CEO, and Carl Morris, Ph.D., Chief Scientific Officer, will participate at the following two upcoming investor conferences.

Ocuphire Pharma, Inc. announced that it has appointed seven new Key Opinion Leaders across retina, cornea/refractive, and medical optometry to its Medical Advisory Board.

Femasys Inc. announced the commercial availability of FemCerv®, the first endocervical tissue sampler designed to improve tissue quality and quantity that is expected to be an improvement over the existing standard of care.